N30 Pharmaceutical appoints Jon Congleton CEO
This article was originally published in Scrip
Executive Summary
Boulder, Colorado-based N30 Pharmaceuticals, a clinical-stage, biopharmaceutical company focused on the development of therapies for cystic fibrosis, has named Jon Congleton president and CEO. Mr Congleton will also join the company's board of directors. He joins the firm from Teva Pharmaceuticals, where over 18 years he held positions in general management and global strategic marketing, including senior vice-president of Teva's Central Nervous System Global Franchise, senior VP of the Global Medicines Group, and general manager of Teva Neuroscience.